Exscientia plc (EXAI)

NASDAQ: EXAI · IEX Real-Time Price · USD
5.11
+0.15 (3.02%)
Dec 9, 2022 4:00 PM EST - Market closed
3.02%
Market Cap 609.47M
Revenue (ttm) 28.55M
Net Income (ttm) -115.96M
Shares Out 122.46M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 200,205
Open 4.96
Previous Close 4.96
Day's Range 4.96 - 5.28
52-Week Range 4.9 - 24.99
Beta n/a
Analysts Buy
Price Target 15.30 (+199.4%)
Earnings Date Nov 15, 2022

About EXAI

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 an... [Read more]

Industry Biotechnology
IPO Date Oct 1, 2021
Employees 285
Stock Exchange NASDAQ
Ticker Symbol EXAI
Full Company Profile

Financial Performance

In 2021, Exscientia's revenue was 27.36 million, an increase of 182.87% compared to the previous year's 9.67 million. Losses were -49.23 million, 120.9% more than in 2020.

Financial numbers in GBP Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for EXAI stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 199.41% from the latest price.

Price Target
$15.3
(199.41% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress

VIENNA, Austria & OXFORD, England--( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI) today highlighted new data to identify patients that are more likely to respond to its A2A receptor antagonist, EXS-21...

3 days ago - Business Wire

Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advance...

OXFORD, England--( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI) today announced clinical trial application (CTA) approval of IGNITE-AI, enabling site activation in its first European country. IGNITE-A...

1 week ago - Business Wire

Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates

Exscientia PLC Sponsored ADR (EXAI) delivered earnings and revenue surprises of -72.73% and 47.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t...

3 weeks ago - Zacks Investment Research

Exscientia Business and Financial Update for the Third Quarter 2022

OXFORD, U.K.--( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI)

3 weeks ago - Business Wire

Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

OXFORD, England & HOUSTON, Texas--( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-ce...

3 weeks ago - Business Wire

Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2022, on Tuesday, November 15, 2022, before the open of U.S. markets.

1 month ago - Business Wire

Exscientia Expands Biologics Design Capability with Automated Laboratory

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the expansion of its platform to include the design of biologics, such as human antibodies.

1 month ago - Business Wire

Exscientia to Present at Upcoming Investor Conferences in November

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November: BofA Securities 20...

1 month ago - Business Wire

Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) is honoured to announce that the company has won the Prix Galien USA 2022 Award for Best Digital Health Solution in recognition of its AI-...

1 month ago - Business Wire

Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual ...

VIENNA, Austria & OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today highlighted new data aimed at enriching for patients that are more likely to respond to its precision-designed CDK...

1 month ago - Business Wire

Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patien...

VIENNA & OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Bloo...

2 months ago - Business Wire

Exscientia Welcomes Caroline Rowland as Chief People Officer

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that Caroline Rowland has joined Exscientia as Chief People Officer. In this newly created role, she will lead Exscientia'...

3 months ago - Business Wire

Exscientia to Present at Upcoming Investor Conferences in September

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI) today announced that Company management will participate in the following investor conferences in September: Morgan Stanley Annual Global Heal...

3 months ago - Business Wire

Exscientia Business Update for Second Quarter and First Half 2022

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) Recent developments in the Company's pipeline, collaborations, and operations, as well as financial results for the second quarter and fir...

3 months ago - Business Wire

Exscientia to Report Second Quarter 2022 Financial Results on August 17, 2022

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective ...

3 months ago - Business Wire

Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 63%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 62.6% in Exscientia PLC Sponsored ADR (EXAI). While the effectiveness of this highly sought-after metric is quest...

5 months ago - Zacks Investment Research

Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibitio...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2A receptor antagonist co-invented and d...

Other symbols: EVO
5 months ago - Business Wire

Exscientia to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia's founder and CEO, and Dave Hallett, Chief Operations Officer, will participate in a f...

6 months ago - Business Wire

Exscientia PLC Sponsored ADR (EXAI) Upgraded to Buy: Here's Why

Exscientia PLC Sponsored ADR (EXAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

Exscientia Business Update for First Quarter 2022

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company's pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, ar...

6 months ago - Business Wire

Exscientia to Report First Quarter 2022 Financial Results on May 25, 2022

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective ...

6 months ago - Business Wire

Exscientia to Present at the BofA Securities 2022 Healthcare Conference

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI) today announced that Ben Taylor, CFO & Chief Strategy Officer and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside c...

7 months ago - Business Wire

Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the Ame...

OXFORD, England & VIENNA, Austria--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today shared details of its participation at the upcoming American Association for Cancer Research (AACR) Annual Meeting...

8 months ago - Business Wire

Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Officer

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams ...

8 months ago - Business Wire

Exscientia Business Update for Fourth Quarter and Full Year 2021

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company's pipeline, collaborations and operations as well as financial results for the fourth quarter and full ...

8 months ago - Business Wire